RNA Diagnostics

Toronto, Canada Founded: 2010 • Age: 16 yrs
Diagnostic assays for cancer detection via rRNA disruption are developed.
Request Access

About RNA Diagnostics

RNA Diagnostics is a company based in Toronto (Canada) founded in 2010.. RNA Diagnostics has raised $13.87 million across 5 funding rounds from investors including BDC and iGan Partners. The company has 49 employees as of May 27, 2025. RNA Diagnostics offers products and services including Veridapt DX. RNA Diagnostics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.

  • Headquarter Toronto, Canada
  • Employees 49 as on 27 May, 2025
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Rna Diagnostics Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $13.87 M (USD)

    in 5 rounds

  • Latest Funding Round
    $34.71 K (USD), Series A

    Dec 19, 2024

  • Investors
    BDC

    & 1 more

  • Employee Count
    49

    as on May 27, 2025

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of RNA Diagnostics

RNA Diagnostics offers a comprehensive portfolio of products and services, including Veridapt DX. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Measures early tumor response to cancer drugs for treatment guidance.

People of RNA Diagnostics
Headcount 10-50
Employee Profiles 2
Employee Profiles
People
Laura Pritzker
VP Operations and R&D
People
John Connolly
Chief Executive Officer

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of RNA Diagnostics

RNA Diagnostics has successfully raised a total of $13.87M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $34.71 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series A — $34,710
  • First Round

    (21 Sep 2015)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2024 Amount Series A - RNA Diagnostics Valuation

investors

Nov, 2024 Amount Series A - RNA Diagnostics Valuation

investors

Sep, 2021 Amount Series A - RNA Diagnostics Valuation BDC
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in RNA Diagnostics

RNA Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BDC and iGan Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Healthcare-focused venture capital is provided by iGan Partners.
Founded Year Domain Location
Commercial banking services for small and medium-sized enterprises are provided.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by RNA Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - RNA Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Rna Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of RNA Diagnostics

RNA Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
domain founded_year HQ Location
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
domain founded_year HQ Location
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
domain founded_year HQ Location
Therapeutics for aging diseases are developed by targeting senescent cells.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Rna Diagnostics

Frequently Asked Questions about RNA Diagnostics

When was RNA Diagnostics founded?

RNA Diagnostics was founded in 2010 and raised its 1st funding round 5 years after it was founded.

Where is RNA Diagnostics located?

RNA Diagnostics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Is RNA Diagnostics a funded company?

RNA Diagnostics is a funded company, having raised a total of $13.87M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Sep 21, 2015.

How many employees does RNA Diagnostics have?

As of May 27, 2025, the latest employee count at RNA Diagnostics is 49.

What does RNA Diagnostics do?

RNA Diagnostics was established in 2010 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing diagnostic assays to detect cancer, particularly breast cancer. The primary product, RNA Disruption Assay (RDA), is utilized to evaluate chemotherapy response by analyzing rRNA disruption levels in biopsy samples. Operations center on advancing these assays for clinical applications in oncology.

Who are the top competitors of RNA Diagnostics?

RNA Diagnostics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.

What products or services does RNA Diagnostics offer?

RNA Diagnostics offers Veridapt DX.

Who are RNA Diagnostics's investors?

RNA Diagnostics has 2 investors. Key investors include BDC, and iGan Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available